Home > Boards > US Listed > Biotechs > Cellectar Biosciences Inc. (CLRB)

Still lining their FDA ducks up:

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Crusader Member Profile
 
Followed By 91
Posts 5,744
Boards Moderated 0
Alias Born 06/05/08
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 7/1/2020 4:02:31 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/25/2020 4:24:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/25/2020 4:24:05 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/25/2020 4:23:45 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/25/2020 4:22:59 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/25/2020 4:22:13 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/25/2020 4:02:12 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 6/12/2020 4:19:04 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 6/12/2020 4:10:12 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/11/2020 4:35:08 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 6/10/2020 6:33:36 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/8/2020 4:12:59 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/8/2020 4:09:44 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/8/2020 4:09:04 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/8/2020 4:08:23 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/5/2020 4:31:08 PM
Prospectus Filed Pursuant to Rule 424(b)(4) (424b4) Edgar (US Regulatory) - 6/4/2020 6:03:01 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/3/2020 9:15:54 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 6/3/2020 6:01:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/1/2020 8:31:01 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/26/2020 8:15:53 AM
Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp) Edgar (US Regulatory) - 5/20/2020 6:31:53 AM
Securities Registration Statement (s-1/a) Edgar (US Regulatory) - 5/20/2020 6:05:50 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/14/2020 4:03:00 PM
Securities Registration Statement (s-1) Edgar (US Regulatory) - 5/8/2020 5:12:03 PM
Crusader   Monday, 01/06/20 02:40:31 PM
Re: None
Post # of 7986 
Still lining their FDA ducks up:

Cellectar Biosciences Gets Orphan Drug Designation for Lymphona Treatment
BY Dow Jones & Company, Inc.
— 8:46 AM ET 01/06/2020
Cellectar Biosciences Inc. (CLRB) said Monday the U.S. Food and Drug Administration's Office of Orphan Products Development has granted Orphan Drug Designation to CLR 131 in lymphoplasmacytic lymphoma.
The company said CLR 131 is its lead Phospholipid Drug Conjugate product candidate currently in a Phase 2 clinical study in relapsed or refractory select B-cell lymphomas, including lymphoplasmacytic lymphoma.
Cellectar said CLR 131 has previously been granted Orphan Drug designation for the treatment of multiple myeloma by both the U.S. and the European Commission and Rare Pediatric Disease and Orphan Drug designations for the treatments of neuroblastoma, rhabdomyosarcoma, osteosarcoma and Ewing's sarcoma.
Cellectar shares were up 9% to $2.50 premarket.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist